We have also dedicated significant resources to developing novel sequencing technologies to identify genetic alteration in cancer. We have made major strides in bringing high-throughput genotyping tools into the clinic and been involved in national consortia and large multi-center clinical trials such as NCI-MATCH. We have developed the Anchored Multiplex PCR methodology for NGS-based detection of gene fusions and gene mutations. These assays have been implemented at MGH and across many labs world-wide. Most recently we have developed and validated clinical assays for detection of circulating tumor DNA.